ADMA Biologics Reports Third Quarter 2026 Financial Results And Provides Business Update
| WARNING: THROMBOSIS, RENAL DYSFUNCTION AND ACUTE RENAL FAILURE |
| Thrombosis may occur with immune globulin intravenous (IGIV) products, including ASCENIV. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with the administration of IGIV products in predisposed patients. Such events require immediate medical intervention, if not recognized or managed appropriately, may result in persistent or significant disability or lead to fatal outcome. For patients at risk of thrombosis, renal dysfunction or renal failure, administer ASCENIV at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. |
ASCENIVTM Contraindications:
History of anaphylactic or severe systemic reactions to human immunoglobulin.
IgA deficient patients with antibodies to IgA and a history of hypersensitivity.
ASCENIVTM Warnings and Precautions:
IgA-deficient patients with antibodies against IgA are at greater risk of developing severe hypersensitivity and anaphylactic reactions. Have medications such as epinephrine available to treat any acute severe hypersensitivity reactions. [4, 5.1]
Thrombotic events have occurred in patients receiving IGIV treatments. Monitor patients with known risk factors for thrombotic events; consider baseline assessment of blood viscosity for patients at risk of hyperviscosity. [5.2, 5.4]
In patients at risk of developing acute renal failure, monitor renal function, including blood urea nitrogen (BUN), serum creatinine, and urine output. [5.3, 5.9]
Hyperproteinemia, increased serum viscosity, and hyponatremia or pseudohyponatremia can occur in patients receiving IGIV treatment. [5.4]
Aseptic meningitis syndrome (AMS) has been reported with IGIV treatments, especially with high doses or rapid infusion. [5.5]
Hemolytic anemia can develop subsequent to IGIV treatment. Monitor patients for hemolysis and hemolytic anemia. [5.6]
Monitor patients for pulmonary adverse reactions (Transfusion-related acute lung injury [TRALI]). If transfusion-related acute lung injury is suspected, test the product and patient for antineutrophil antibodies. [5.7]
Because this product is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. [5.8]
ASCENIVTM Adverse Reactions:
The most common adverse reactions to ASCENIV (≥5% of study subjects) were headache, sinusitis, diarrhea, gastroenteritis viral, nasopharyngitis, upper respiratory tract infection, bronchitis, and nausea.
To report SUSPECTED ADVERSE REACTIONS, contact ADMA Biologics at (800) 458-4244 or the FDA at 1-800-FDA-1088 or .
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. ADMA currently manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics: ASCENIVTM (immune globulin intravenous, human – slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM® (immune globulin intravenous, human) for the treatment of PI; and NABI-HB® (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Additionally, ADMA is developing SG-001, a pre-clinical, investigative hyperimmune globulin targeting S. pneumoniae. ADMA manufactures its immune globulin products and product candidates at its FDA-licensed plasma fractionation and purification facility located in Boca Raton, Florida. Through its ADMA BioCenters subsidiary, ADMA also operates as an FDA-approved source plasma collector in the U.S., which provides a portion of its blood plasma for the manufacture of its products and product candidates. ADMA's mission is to manufacture, market and develop specialty plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations who suffer from an underlying immune deficiency, or who may be immune compromised for other medical reasons.
ADMA holds numerous U.S. and foreign patents related to and encompassing various aspects of its products and product candidates. For more information, please visit .
Use of Non-GAAP Financial Measures
This press release includes certain non-GAAP financial measures that are not prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The Company believes Adjusted EBITDA, Adjusted Net Income, and Adjusted Basic EPS are useful to investors in evaluating the Company's financial performance. The Company uses Adjusted EBITDA, Adjusted Net Income and Adjusted Basic EPS as key performance measures because it believes that they facilitate operating performance comparisons from period to period that exclude potential differences driven by the impact of variations of non-cash items such as depreciation and amortization, as well as, in the case of Adjusted EBITDA, stock-based compensation or certain non-recurring items, in the case of Adjusted Net Income, certain non-recurring items, and in the case of Adjusted Basic EPS, the impact of the adjustments reflected in Adjusted Net Income on basic weighted average outstanding shares. The Company believes that investors should have access to the same set of tools used by its management and Board of Directors to assess its operating performance. Adjusted EBITDA, Adjusted Net Income and Adjusted Basic EPS should not be considered as measures of financial performance under GAAP, and the items excluded from Adjusted EBITDA, Adjusted Net Income and Adjusted Basic EPS are significant components in understanding and assessing the Company's financial performance. Accordingly, these key business metrics have limitations as an analytical tool. They should not be considered as an alternative to net income, cash flows from operations, or any other performance measures derived in accordance with GAAP and may be different from similarly titled non-GAAP measures used by other companies. Please refer to the tables below for the reconciliation of GAAP measures to these non-GAAP measures for applicable periods.
The Company has not provided a reconciliation of its forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measure because certain items that are excluded from such non-GAAP financial measures cannot be reasonably predicted or estimated without unreasonable effort. These items may include, but are not limited to, costs associated with potential business development, licensing, collaboration, acquisition, divestiture or other strategic transactions; unusual legal, litigation, regulatory, settlement and related professional fees, expenses and other organizational optimization costs; and other unusual, non-recurring, infrequent or non-cash items that may arise during the applicable period.
The timing, occurrence, and magnitude of these items are inherently uncertain and depend on a variety of factors that are outside of the Company's control or cannot be reasonably predicted at this time. Accordingly, management is unable to estimate these amounts with reasonable certainty or determine the probable significance of such items to the corresponding GAAP financial measure without unreasonable effort. These items could have a material impact on the Company's GAAP results for the applicable reporting period.
Cautionary Note Regarding Forward-Looking Statements
This press release contains“forward-looking statements” pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. (“we,”“our” or the“Company”). Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain such words as“confident,”“estimate,”“project,”“intend,”“forecast,”“target,”“anticipate,”“plan,”“planning,”“expect,”“believe,”“will,”“is likely,”“will likely,”“position us,”“positioned,”“support,”“should,”“could,”“would,”“may,”“potential,”“view,”“opportunity” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements about: the Company's total revenue, Adjusted Net Income, Adjusted EBITDA, earnings and earnings potential, profitability, scalability, financial guidance in future periods and related assumptions; the Company's ability to generate stockholder value and related drivers; the current U.S. immune globulin market, including competitive pressures and conditions; ASCENIV revenue growth and potential, value proposition, market opportunity, growth trajectory, appropriate market, adoption, demand and utilization; our ability and plans to complete our 2026 share repurchase target; real-world health outcomes evidence (including, but not limited to, certain patient analyses expected to be presented) and the beneficial impact for ASCENIV's clinical value and commercial adoption; BIVIGAM potential with signs of stabilization in underlying BIVIGAM utilization; and SG-001, its data, regulatory filings and submissions, revenue potential, growth opportunity and clinical development plans and timeline, the incorporation of FDA feedback into the final clinical protocol, preparations for an IND submission, the potential efficiency of the development pathway, as well as our ability to leverage our existing manufacturing infrastructure in the development of SG-001. Actual events or results may differ materially from those described in this press release due to a number of important factors. Current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the SEC, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.
(1) Adjusted Net Income is a non-GAAP financial measure. The most directly comparable financial measure calculated and presented in accordance with GAAP is Net Income. For a reconciliation of Adjusted Net Income to Net Income, see the reconciliation included in the financial tables. All non-GAAP adjustments are presented pre-tax.
(2) Adjusted Basic EPS is a non-GAAP financial measure. The most directly comparable financial measure calculated and presented in accordance with GAAP is Basic EPS. For a reconciliation of Adjusted Basic EPS to Basic EPS, see the reconciliation included in the financial tables. All non-GAAP adjustments are presented pre-tax.
(3) Adjusted EBITDA is a non-GAAP financial measure. The most directly comparable financial measure calculated and presented in accordance with GAAP is Net Income. For a reconciliation of Adjusted EBITDA to Net Income, see the reconciliation included in the financial tables.
INVESTOR RELATIONS CONTACT:
Argot Partners | 212-600-1902 | ...
MEDIA CONTACT:
Longacre Square Partners | ...
| ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS | ||||||||
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (in thousands, except share and per share data) | ||||||||
| Unaudited | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 124,555 | $ | 87,630 | ||||
| Accounts receivable, net | 169,223 | 158,429 | ||||||
| Inventories, net | 266,115 | 206,465 | ||||||
| Prepaid expenses and other current assets | 15,969 | 7,458 | ||||||
| Assets held for sale | - | 6,530 | ||||||
| Total current assets | 575,862 | 466,512 | ||||||
| Property and equipment, net | 66,761 | 65,057 | ||||||
| Intangible assets, net | 581 | 632 | ||||||
| Goodwill | 3,530 | 3,530 | ||||||
| Deferred tax assets, net | 70,693 | 73,261 | ||||||
| Right-of-use assets | 5,881 | 6,650 | ||||||
| Deposits and other assets | 9,177 | 8,600 | ||||||
| TOTAL ASSETS | $ | 732,485 | $ | 624,242 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 35,660 | $ | 22,519 | ||||
| Accrued expenses and other current liabilities | 54,217 | 40,466 | ||||||
| Current portion of long-term debt | 4,219 | 2,813 | ||||||
| Current portion of lease obligations | 1,180 | 1,096 | ||||||
| Liabilities held for sale | - | 2,647 | ||||||
| Total current liabilities | 95,276 | 69,541 | ||||||
| Long-term debt | 191,638 | 69,330 | ||||||
| Deferred revenue, net of current portion | 1,297 | 1,405 | ||||||
| Lease obligations, net of current portion | 5,767 | 6,646 | ||||||
| TOTAL LIABILITIES | $ | 293,978 | $ | 146,922 | ||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| STOCKHOLDERS' EQUITY | ||||||||
| Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, | ||||||||
| no shares issued and outstanding | - | - | ||||||
| Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, | ||||||||
| September 30, 2026: 241,251,158 issued and 222,793,831 outstanding; December 31, 2025: 239,793,566 issued and 237,874,496 outstanding | 24 | 24 | ||||||
| Treasury stock, at cost, 18,457,327 and 1,919,070 shares as of September 30, 2026 | ||||||||
| and December 31, 2025, respectively | (213,736 | ) | (32,090 | ) | ||||
| Additional paid-in capital | 680,838 | 671,039 | ||||||
| Accumulated deficit | (28,619 | ) | (161,653 | ) | ||||
| TOTAL STOCKHOLDERS' EQUITY | 438,507 | 477,320 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 732,485 | $ | 624,242 | ||||
| ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS NON-GAAP RECONCILIATION | |||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| (in thousands, except share and per share data) | |||||||||||||||||
| Unaudited | |||||||||||||||||
| REVENUES | $ | 141,102 | $ | 134,224 | $ | 379,990 | $ | 371,010 | |||||||||
| Cost of product revenue | 41,185 | 58,598 | 113,046 | 167,061 | |||||||||||||
| Gross profit | 99,917 | 75,626 | 266,944 | 203,949 | |||||||||||||
| OPERATING EXPENSES: | |||||||||||||||||
| Research and development | 4,490 | 1,528 | 13,101 | 3,386 | |||||||||||||
| Plasma center operating expenses | 1,055 | 1,272 | 3,143 | 3,710 | |||||||||||||
| Amortization of intangible assets | 60 | 38 | 170 | 93 | |||||||||||||
| Gain on sale of plasma centers | - | - | (7,980 | ) | - | ||||||||||||
| Selling, general and administrative | 26,555 | 21,776 | 80,034 | 68,068 | |||||||||||||
| Total operating expenses | 32,160 | 24,614 | 88,468 | 75,257 | |||||||||||||
| INCOME FROM OPERATIONS | 67,757 | 51,012 | 178,476 | 128,692 | |||||||||||||
| OTHER INCOME (EXPENSE): | |||||||||||||||||
| Interest and other income | 1,298 | 376 | 3,629 | 1,384 | |||||||||||||
| Interest expense | (3,432 | ) | (1,675 | ) | (8,956 | ) | (5,484 | ) | |||||||||
| Loss on extinguishment of debt | - | (2,177 | ) | - | (3,336 | ) | |||||||||||
| Other expense | (19 | ) | (21 | ) | (180 | ) | (195 | ) | |||||||||
| Other income (expense), net | (2,153 | ) | (3,497 | ) | (5,507 | ) | (7,631 | ) | |||||||||
| INCOME BEFORE INCOME TAXES | 65,604 | 47,515 | 172,969 | 121,061 | |||||||||||||
| Provision for income taxes | - | 15,720 | 11,087 | 39,935 | 23,510 | ||||||||||||
| NET INCOME | $ | 49,884 | $ | 36,428 | $ | 133,034 | $ | 97,551 | |||||||||
| BASIC EARNINGS PER COMMON SHARE | $ | 0.22 | $ | 0.15 | $ | 0.58 | $ | 0.41 | |||||||||
| DILUTED EARNINGS PER COMMON SHARE | $ | 0.22 | $ | 0.15 | $ | 0.57 | $ | 0.40 | |||||||||
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | |||||||||||||||||
| Basic | 223,695,193 | 238,602,978 | 229,291,798 | 238,408,042 | |||||||||||||
| Diluted | 225,820,678 | 244,664,263 | 232,105,293 | 245,491,334 | |||||||||||||
| RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA(3) | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||
| (in thousands) | |||||||||||||
| Unaudited | |||||||||||||
| Net income | $ | 49,884 | $ | 36,428 | $ | 133,034 | $ | 97,551 | |||||
| Depreciation | 1,729 | 1,987 | 5,239 | 5,957 | |||||||||
| Amortization | 60 | 38 | 170 | 93 | |||||||||
| Income taxes | 15,720 | 11,087 | 39,935 | 23,510 | |||||||||
| Interest expense, net | 2,134 | 1,675 | 5,303 | 5,484 | |||||||||
| EBITDA | 69,527 | 51,215 | 183,681 | 132,595 | |||||||||
| Stock-based compensation | 6,203 | 5,047 | 18,666 | 14,634 | |||||||||
| Voluntary Withdrawal and product replacements | - | - | - | 4,001 | |||||||||
| Yield enhancement | 181 | 301 | 1,022 | 1,696 | |||||||||
| Gain on sale of plasma centers | - | - | (7,980 | ) | - | ||||||||
| Loss on extinguishment of debt | - | 2,177 | - | 3,336 | |||||||||
| Non-recurring professional fees | 1,368 | - | 3,388 | 1,182 | |||||||||
| Adjusted EBITDA | $ | 77,279 | $ | 58,740 | $ | 198,777 | $ | 157,444 | |||||
| NON-GAAP RECONCILIATION RECONCILIATION OF GAAP NET INCOME TO ADJUSTED NET INCOME(1) | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||
| (in thousands) | |||||||||||||
| Unaudited | |||||||||||||
| Net income | $ | 49,884 | $ | 36,428 | $ | 133,034 | $ | 97,551 | |||||
| Stock-based compensation modifications | - | - | 609 | 474 | |||||||||
| Customer credits related to the Voluntary Withdrawal | - | - | - | 4,001 | |||||||||
| Loss on extinguishment of debt | - | 2,177 | - | 3,336 | |||||||||
| Yield Enhancement | 138 | 301 | 788 | 1,696 | |||||||||
| Gain on sale of plasma centers | - | - | (6,332 | ) | - | ||||||||
| Non-recurring professional fees | 1,040 | - | 2,599 | 1,182 | |||||||||
| Adjusted net income (a) | $ | 51,062 | $ | 38,906 | $ | 130,698 | $ | 108,240 | |||||
| (a) Add-backs reflected during the three and nine months ended September 30, 2025 exclude estimated tax effect of $0.6 million and $2.1 million, respectively. Add-backs reflected during the three months and nine months ended September 30, 2026 were tax affected using the respective effective tax rates. | |||||||||||||
| NON-GAAP RECONCILIATION RECONCILIATION OF BASIC EARNINGS PER SHARE TO ADJUSTED EARNINGS PER SHARE(2) | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||
| (in thousands) | |||||||||||||
| Unaudited | |||||||||||||
| Net income | $ | 49,884 | $ | 36,428 | $ | 133,034 | $ | 97,551 | |||||
| Stock-based compensation modifications | - | - | 609 | 474 | |||||||||
| Customer credits related to the Voluntary Withdrawal | - | - | - | 4,001 | |||||||||
| Loss on extinguishment of debt | - | 2,177 | - | 3,336 | |||||||||
| Yield Enhancement | 138 | 301 | 788 | 1,696 | |||||||||
| Gain on sale of plasma centers | - | - | (6,332 | ) | - | ||||||||
| Non-recurring professional fees | 1,040 | - | 2,599 | 1,182 | |||||||||
| Adjusted net income (a) | $ | 51,062 | $ | 38,906 | $ | 130,698 | $ | 108,240 | |||||
| Basic earnings per common share | $ | 0.22 | $ | 0.15 | $ | 0.58 | $ | 0.41 | |||||
| Stock-based compensation modifications | - | - | - | - | |||||||||
| Customer credits related to the Voluntary Withdrawal | - | - | - | 0.02 | |||||||||
| Loss on extinguishment of debt | - | 0.01 | - | 0.01 | |||||||||
| Yield Enhancement | - | - | - | 0.01 | |||||||||
| Gain on sale of plasma centers | - | - | (0.03 | ) | - | ||||||||
| Non-recurring professional fees | 0.01 | - | 0.01 | - | |||||||||
| Adjusted basic EPS (b) | $ | 0.23 | $ | 0.16 | $ | 0.56 | $ | 0.45 | |||||
| (a) Add-backs reflected during the three and nine months ended September 30, 2025 exclude estimated tax effect of $0.6 million and $2.1 million, respectively. Add-backs reflected during the three months and nine months ended September 30, 2026 were tax affected using the respective effective tax rates. | |||||||||||||
| (b) Adjusted basic EPS is measured using basic weighted-average shares outstanding. | |||||||||||||
| PRODUCT-LEVEL TOTAL REVENUE | |||||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||||
| 2026 | 2025 | Increase/ (Decrease) | Increase/ (Decrease) % | 2026 | 2025 | Increase/ (Decrease) | Increase/ (Decrease) % | ||||||||||||||||||
| (in thousands) | Unaudited | ||||||||||||||||||||||||
| ASCENIV | $ | 124,742 | $ | 95,410 | $ | 29,332 | 30.7 | % | $ | 325,149 | $ | 255,063 | $ | 70,086 | 27.5 | % | |||||||||
| BIVIGAM | 15,390 | 23,763 | (8,373 | ) | (35.2 | %) | 50,231 | 94,984 | (44,753 | ) | (47.1 | %) | |||||||||||||
| Intermediates and other products (1) | 909 | 15,015 | (14,106 | ) | (93.9 | %) | 3,039 | 19,806 | (16,767 | ) | (84.7 | %) | |||||||||||||
| ADMA BioManufacturing | 141,041 | 134,188 | 6,853 | 5.1 | % | 378,419 | 369,853 | 8,567 | 2.3 | % | |||||||||||||||
| Plasma Collection Centers | 25 | - | 25 | 100.0 | % | 1,464 | 1,050 | 414 | 39.4 | % | |||||||||||||||
| License revenue | 36 | 36 | - | 0.0 | % | 107 | 107 | - | 0.0 | % | |||||||||||||||
| Total Revenues | $ | 141,102 | $ | 134,224 | $ | 6,878 | 5.1 | % | $ | 379,990 | $ | 371,010 | $ | 8,981 | 2.4 | % | |||||||||
| (1) Due to Nabi-HB historically representing less than 10% of the Company's revenue within the ADMA BioManufacturing segment, it has been included under intermediates and other products. | |||||||||||||||||||||||||
| ADMA BIOLOGICS, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENT OF CASH FLOWS | ||||||||||||
| Nine Months Ended September 30, | ||||||||||||
| 2026 | 2025 | |||||||||||
| (In thousands) | ||||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||||||
| Net income | 133,034 | 97,551 | ||||||||||
| Adjustments to reconcile net income to net | ||||||||||||
| cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | 5,409 | 6,050 | ||||||||||
| Gain on sale of plasma centers | (7,980 | ) | - | |||||||||
| Loss on disposal of fixed assets | 42 | - | ||||||||||
| Deferred income tax provision | 2,569 | 9,848 | ||||||||||
| Stock-based compensation | 18,667 | 14,634 | ||||||||||
| Amortization of debt discount | 589 | 520 | ||||||||||
| Loss on extinguishment of debt | - | 3,336 | ||||||||||
| Amortization of license revenue | (107 | ) | (107 | ) | ||||||||
| Changes in operating assets and liabilities: | ||||||||||||
| Accounts receivable, net | (10,794 | ) | (87,674 | ) | ||||||||
| Inventories | (59,650 | ) | (26,432 | ) | ||||||||
| Prepaid expenses and other current assets | (2,514 | ) | (978 | ) | ||||||||
| Deposits and other assets | 192 | (261 | ) | |||||||||
| Accounts payable | 12,958 | 4,533 | ||||||||||
| Accrued expenses | 13,675 | (5,427 | ) | |||||||||
| Other current and non-current liabilities | (934 | ) | (836 | ) | ||||||||
| Net cash provided by operating activities | 105,156 | 14,757 | ||||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||||||
| Purchase of property and equipment | (6,801 | ) | (21,491 | ) | ||||||||
| Acquisition of intangible assets | (119 | ) | (124 | ) | ||||||||
| Proceeds on the sales of assets held for sale | 5,000 | - | ||||||||||
| Net cash used in investing activities | (1,920 | ) | (21,615 | ) | ||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||||||
| Ares term loan payments | - | (32,500 | ) | |||||||||
| Ares revolving facility payments | - | (72,500 | ) | |||||||||
| Ares revolving facility proceeds | - | 30,000 | ||||||||||
| JPM term loan payments | (1,875 | ) | (469 | ) | ||||||||
| JPM revolving facility proceeds | 125,000 | 75,000 | ||||||||||
| Prepayment penalties on repayment of debt | - | (1,031 | ) | |||||||||
| Taxes paid on vested restricted stock units | (9,769 | ) | (9,383 | ) | ||||||||
| Debt issuance costs | - | (2,224 | ) | |||||||||
| Net proceeds from the exercise of stock options | 633 | 2,554 | ||||||||||
| Payment of end of term fee | - | (1,313 | ) | |||||||||
| Acquisition of treasury stock | (180,300 | ) | (23,038 | ) | ||||||||
| Net cash used in financing activities | (66,311 | ) | (34,904 | ) | ||||||||
| Net increase (decrease) in cash and cash equivalents | 36,925 | (41,762 | ) | |||||||||
| Cash and cash equivalents - beginning of period | 87,630 | 103,147 | ||||||||||
| Cash and cash equivalents - end of period | $ | 124,555 | $ | 61,385 |
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Comments
No comment